ISSN:
1435-1463
Keywords:
Spiperone binding
;
Parkinson's disease
;
multiple system atrophy
;
vascular lesions
;
differential diagnosis
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary In order to investigate the diagnostic value of3H-spiperone binding capacity to lymphocytes in the differential diagnosis of de novo Parkinson's disease (idiopathic Parkinson syndrome, PD), we performed a double blind prospective study of spiperone binding capacity of 123 patients and 23 healthy control persons, belonging to different diagnostic groups (PD, Parkinsonian syndrome due to vascular lesions, multiple system atrophy [MSA], essential tremor). Diagnoses were based on medical history, clinical examination, CT or MRI scan, acute response to dopamimetric drugs, one year follow up, and long term response to L-DOPA treatment. Spiperone binding was assayed using ten different concentrations (0.03–3 nmol) in absence or presence of 1μmol (+)-butaclamol to determine nonsepecific binding. There was no significant difference in spiperone binding between patients with PD not treated with L-DOPA, and patients with other basal ganglia disorders including parkinsonian syndrome due to vascular lesions, multiple system atrophy, or progressive supranuclear palsy, and age matched controls. Binding was significantly higher in parkinsonian patients with PD treated with L-DOPA and patients with essential tremor. It is concluded that at present3H-spiperone binding gives no further information in the differential diagnosis of de novo Parkinson's disease.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF02251201
Permalink
